4 terminated, 2 recruiting, 1 enrolling by invitation. 6 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Terminated 4, Recruiting 2 |
| Phase 2 | 1 | Recruiting 1 |
Follow AvenCell Europe GmbH: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials UniCAR02-T (IMP) With Targeting Module TM123, UniCAR02-T-pPSMA, Allo-RevCAR01- T with Targeting Module R-TM123 - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Enrolling by invitation | AvenCell Therapeutics, Inc. | 178 | 2026-01-29 | 2026-03-16 | |
| Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), Allo-QuadCAR01-T - Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma | Phase 1 / Phase 2 | Recruiting | AvenCell Therapeutics, Inc. | 178 | 2026-01-06 | 2026-08-28 |
| Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion) Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), R-TM123 - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 | Recruiting | AvenCell Europe GmbH | 37 | 2024-01-03 | 2026-09-24 |
| Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker Cyclophosphamide (Non-IMP), Fludarabine (Non-IMP), UniCAR02-T-pPSMA - Prostate Cancer | Phase 1 | Terminated | AvenCell Europe GmbH | 16 | 2020-11-23 | 2024-04-23 |
| Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies Cyclophosphamide (Non-IMP), Fludarabine (Non-IMP), TM123 (IMP) - Acute Myeloid Leukemia (AML) | Phase 1 | Terminated | AvenCell Europe GmbH | 32 | 2020-01-28 | 2026-01-22 |
| Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker GEM3PSCA - Non-small Cell Lung Cancer, Prostate Cancer | Phase 1 | Terminated | AvenCell Europe GmbH | 23 | 2019-04-15 | 2023-07-10 |
| Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia GEM333 - Acute Myeloid Leukemia, Relapsed AML | Phase 1 | Terminated | AvenCell Europe GmbH | 36 | 2018-04-11 | 2022-09-29 |
Leukemia, Myeloid, Acute (4) · Prostatic Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Hematologic Neoplasms (1) · Kidney Neoplasms (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1)
Cyclophosphamide (4) · fludarabine (4) · Inosine Monophosphate (3)
Germany (7) · Netherlands (2) · United States (1)
Manfred Klevesath, MD (1) · Martin Wermke, MD (1) · Ralf Bargou, Prof. (1) · Ralf Bargou, Prof. Dr. (1)
2019 (2), 2017 (1), 2025 (1)